Trial Profile
Clinical non-inferiority study between Micronized purified flavonoid fraction 1000 mg, one chewable tablet per day and Micronized Purified Flavonoid Fraction 500 mg, 2 tablets daily after eight weeks of treatment in patients suffering from symptomatic Chronic Venous Disease (CVD). International, multicenter, double-blind, randomized, parallel group study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 May 2022
Price :
$35
*
At a glance
- Drugs S 5682 (Primary) ; Diosmin/hesperidin
- Indications Venous insufficiency
- Focus Registrational; Therapeutic Use
- Sponsors IRIS
- 05 Jan 2020 Status changed from recruiting to completed.
- 23 May 2018 New trial record